BIOMAT Database Logo BIOMAT Database Logo

Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs. 1993

A C Allison, and E M Eugui
Institute of Immunology and Biological Sciences, Syntex Research, Palo Alto, California 94002.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000963 Antimetabolites Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) Antimetabolite

Related Publications

A C Allison, and E M Eugui
Potent inhibitors of de novo pyrimidine and purine biosynthesis as chemotherapeutic agents.
January 1990, Medicinal research reviews,
A C Allison, and E M Eugui
Purine nucleoside inhibitors of purine biosynthesis de novo.
November 1968, Cancer chemotherapy reports. Part 2,
A C Allison, and E M Eugui
Some pyrazoles as inhibitors of purine biosynthesis de novo.
April 1976, Biochemical pharmacology,
A C Allison, and E M Eugui
Folate-deficient human lymphoblasts: changes in de novo purine and pyrimidine synthesis and phosphoribosylpyrophosphate.
September 1991, European journal of haematology,
A C Allison, and E M Eugui
Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors.
February 1993, Transplantation proceedings,
A C Allison, and E M Eugui
[Purine de novo-synthesis in lymphocytes].
January 1971, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
A C Allison, and E M Eugui
Enzymatic de novo pyrimidine nucleotide synthesis.
January 2011, Journal of the American Chemical Society,
A C Allison, and E M Eugui
Inhibitors of de novo nucleotide biosynthesis as drugs.
November 2002, Accounts of chemical research,
A C Allison, and E M Eugui
Effect of de novo purine synthesis inhibitors on 5-fluorouracil metabolism and cytotoxicity.
September 1981, Biochemical pharmacology,
A C Allison, and E M Eugui
Simultaneous estimation of rates of pyrimidine and purine nucleotide synthesis de novo in cultured human cells.
December 1979, The Journal of biological chemistry,
Copied contents to your clipboard!